METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS
First Claim
1. A method of preserving visual function of an eye of a subject with an ocular condition selected from the group consisting of glaucoma, optic nerve injury, and optic neuritis, wherein a symptom of the ocular condition is the loss of retinal ganglion cell viability in the retina of the eye with the condition, the method comprising:
- (a) administering to the eye of the subject an effective amount of a necrosis inhibitor selected from the group consisting of necrostatin-1, necrostatin-2, necrostatin-3, necrostatin-4, necrostatin-5, necrostatin-7, and related compounds, and an effective amount of an apoptosis inhibitor selected from the group consisting of pan-caspase inhibitors, caspase-1 inhibitors, caspase-3 inhibitors, caspase-8 inhibitors, and caspase-9 inhibitors, thereby to preserve the viability of retinal ganglion cells disposed within the retina of the eye; and
(b) after step (a), measuring visual function of the eye.
1 Assignment
0 Petitions
Accused Products
Abstract
Provided are methods and compositions for maintaining the viability of retinal ganglion cells in a subject with an ocular disorder including, for example, glaucoma and optic nerve injury. The viability of the retinal ganglion cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells and/or promote axon regeneration, thereby minimizing the loss of vision or visual function associated with the ocular disorder.
-
Citations
49 Claims
-
1. A method of preserving visual function of an eye of a subject with an ocular condition selected from the group consisting of glaucoma, optic nerve injury, and optic neuritis, wherein a symptom of the ocular condition is the loss of retinal ganglion cell viability in the retina of the eye with the condition, the method comprising:
-
(a) administering to the eye of the subject an effective amount of a necrosis inhibitor selected from the group consisting of necrostatin-1, necrostatin-2, necrostatin-3, necrostatin-4, necrostatin-5, necrostatin-7, and related compounds, and an effective amount of an apoptosis inhibitor selected from the group consisting of pan-caspase inhibitors, caspase-1 inhibitors, caspase-3 inhibitors, caspase-8 inhibitors, and caspase-9 inhibitors, thereby to preserve the viability of retinal ganglion cells disposed within the retina of the eye; and (b) after step (a), measuring visual function of the eye. - View Dependent Claims (2, 10, 16, 19, 20, 26, 30, 37, 40, 42, 43, 45, 46, 47, 48)
-
-
3-9. -9. (canceled)
-
11. (canceled)
-
12. A method for promoting axonal regeneration in an eye of a subject with an ocular condition selected from the group consisting of glaucoma, optic nerve injury, and optic neuritis, wherein a symptom of the ocular condition is the loss of retinal ganglion cell viability in the retina of an eye with the condition, the method comprising:
administering to the eye of the subject an effective amount of a necrosis inhibitor selected from the group consisting of necrostatin-1, necrostatin-2, necrostatin-3, necrostatin-4, necrostatin-5, necrostatin-7, and related compounds, and an effective amount of an apoptosis inhibitor selected from the group consisting of pan-caspase inhibitors, caspase-1 inhibitors, caspase-3 inhibitors, caspase-8 inhibitors, and caspase-9 inhibitors, thereby to promote the regeneration of a retinal ganglion cell axon within the retina of the eye. - View Dependent Claims (13, 14)
-
15. (canceled)
-
17-18. -18. (canceled)
-
21-25. -25. (canceled)
-
27-29. -29. (canceled)
-
31-36. -36. (canceled)
-
38-39. -39. (canceled)
-
41. (canceled)
-
44. (canceled)
-
49-64. -64. (canceled)
Specification